Chemistry: molecular biology and microbiology – Virus or bacteriophage – except for viral vector or...
Patent
1996-01-19
2000-10-03
Mosher, Mary E.
Chemistry: molecular biology and microbiology
Virus or bacteriophage, except for viral vector or...
4353201, 435 691, 435 693, 4241991, C12N 701, C12N 1586, A61K 39275
Patent
active
061271632
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
Swinepox virus (SPV) belongs to the family Poxviridae. Viruses belonging to this group are large, double-stranded DNA viruses that characteristically develop in the cytoplasm of the host cell. SPV is the only member of the genus Suipoxvirus. Several features distinguish SPV from other poxviruses. SPV exhibits species specificity (18) compared to other poxviruses such as vaccinia which exhibit a broad host range. SPV infection of tissue culture cell lines also differs dramatically from other poxviruses (24). It has also been demonstrated that SPV does not exhibit antigenic cross-reactivity with vaccinia virus and shows no gross detectable homology at the DNA level with the ortho, lepori, avi or entomopox virus groups (24). Accordingly, what is known and described in the prior art regarding other poxviruses does not pertain a priori to swinepox virus.
SPV is only mildly pathogenic, being characterized by a self-limiting infection with lesions detected only in the skin and regional lymph nodes. Although the SPV infection is quite limited, pigs which have recovered from SPV are refractory to challenge with SPV, indicating development of active immunity (18).
The present invention concerns the use of SPV as a vector for the delivery of vaccine antigens and therapeutic agents to swine. The following properties of SPV support this rationale: SPV is only mildly pathogenic in swine, SPV is species specific, and SPV elicits a protective immune response. Accordingly, SPV is an excellent candidate for a viral vector delivery system, having little intrinsic risk which must be balanced against the benefit contributed by the vector's vaccine and therapeutic properties.
The prior art for this invention stems first from the ability to clone and analyze DNA while in bacterial plasmids. The techniques that are available are detailed for the most part in Maniatis et al., 1983 and Sambrook et al., 1989. These publications teach state of the art general recombinant DNA techniques.
Among the poxviruses, five (vaccinia, fowlpox, canarypox, pigeon, and raccoon pox) have been engineered, previous to this disclosure, to contain foreign DNA sequences. Vaccinia virus has been used extensively to vector foreign genes (25) and is the subject of U.S. Pat. Nos. 4,603,112 and 4,722,848. Similarly, fowlpox has been used to vector foreign genes and is the subject of several patent applications EPA 0 284 416, PCT WO 89/03429, and PCT WO 89/12684. Raccoon pox (10) and Canarypox (31) have been utilized to express antigens from the rabies virus. These examples of insertions of foreign genes into poxviruses do not include an example from the genus Suipoxvirus. Thus, they do not teach methods to genetically engineer swinepox viruses, that is, where to make insertions and how to get expression in swinepox virus.
The idea of using live viruses as delivery systems for antigens has a very long history going back to the first live virus vaccines. The antigens delivered were not foreign but were naturally expressed by the live virus in the vaccines. The use of viruses to deliver foreign antigens in the modern sense became obvious with the recombinant vaccinia virus studies. The vaccinia virus was the vector and various antigens from other disease causing viruses were the foreign antigens, and the vaccine was created by genetic engineering. While the concept became obvious with these disclosures, what was not obvious was the answer to a more practical question of what makes the best candidate virus vector. In answering this question, details of the pathogenicity of the virus, its site of replication, the kind of immune response it elicits, the potential it has to express foreign antigens, its suitability for genetic engineering, its probability of being licensed by regulatory agencies, etc, are all factors in the selection. The prior art does not teach these questions of utility.
The prior art relating to the use of poxviruses to deliver therapeutic agents relates to the use of a vaccinia virus to deliver interleukin-2 (12).
REFERENCES:
patent: 5382425 (1995-01-01), Cochran
Bhat R.A. et al., (1989) Nucleic Acids Research 17: 1159-1176.
Esposito J.J. et al., (1988) Virology 165: 313-316.
Joshi S. et al., (1991) Journal Of Virology 65: 5524-5530.
Flexner C. et al., (1990) Vaccine 8: 17-21.
Kasza L. et al., (1981) Diseases of the Swine 254-260.
Massung R.F. and Moyer R.W. (1991) Virology 180: 347-354.
Massung R.F. and Moyer R.W. (1991) Virology 180: 355-364.
Taylor J. et al., (1991) Vaccine 9: 190-193.
Schinitzlein W.M. and Tripathy D.N. (1991) Virology 181:727-732.
Wachsman M. et al., (1989) Journal of General Virology 70: 2513-2520.
Williams P.P. et al., (1989) Veterinary Immunology and Immunopathology 23:149-159.
Riviere M. et al., (1992) Journal of Virology 66: 3423-3434.
Massung R.F. et al., (1993) Virology 197: 511-528.
Tuboly T. et al., (1993) Research in Veterinary Science 54: 345-350.
Foley P.L. et al., (1991) Annals New York Academy of Science 646: 220-222.
van der Leek M.L. et al., (1994) The Veterinary Record 134: 13-18.
Cochran Mark D.
Junker David E.
Mosher Mary E.
Syntro Corporation
White John P.
LandOfFree
Recombinant swinepox virus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant swinepox virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant swinepox virus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-194218